Antineoplastic therapy in colorectal cancer through proteasome inhibition

American Surgeon

Volumn 69, Issue 1, 2003, Pages 15-23

  Hochwald, Steven N ^a   Lind, D Scott ^a   Malaty, John ^a   Copeland III, Edward M ^a   Moldawer, Lyle L ^a   Mackay, Sally L D ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CASP3 PROTEIN, HUMAN; CASP3 PROTEIN, RAT; CASPASE; CASPASE 3; CYSTEINE PROTEINASE; DEOXYCYTIDINE; DNA; DRUG DERIVATIVE; ENZYME INHIBITOR; ENZYME PRECURSOR; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUPEPTIN; LUCIFERASE; MULTIENZYME COMPLEX; PROTEASOME;

ANIMAL; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CULTURE; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; GEL MOBILITY SHIFT ASSAY; GENE TRANSFER; GENETICS; HUMAN; METABOLISM; RAT; TRANSACTIVATION; UPREGULATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASES; COLORECTAL NEOPLASMS; CYSTEINE ENDOPEPTIDASES; DEOXYCYTIDINE; DNA, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME INHIBITORS; ENZYME PRECURSORS; GENE TRANSFER TECHNIQUES; HUMANS; LEUPEPTINS; LUCIFERASES; MULTIENZYME COMPLEXES; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0037270566     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. CA Cancer J Clin 2000;50:7-33.
2. Negoescu A. Apoptosis in cancer: Therapeutic implications. Histol Histopathol 2000;15:281-297
3. Ghosh S, May M, Kopp E. NF-κB and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-260 (Pubitemid 28183365)
4. Foo SY, Nolan GP. NF-κB to the rescue: RELs, apoptosis and cellular transformation. Trends Genet 1999;15:229-235
5. Wang W, Abbruzzese JL, Evans DB, et al. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-127 (Pubitemid 29045184)
6. Sovak MA, Bellas RE, Kim DW, et al. Aberrant NF-κB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997;100:2952-2960 (Pubitemid 28022831)
7. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997;100:2961-2969 (Pubitemid 28022832)
8. Bours V, Dejardin E, Goujon-Letawe F, et al. The NF-κ B transcription factor and cancer: High expression of NF-κ B- and I κ B-related proteins in tumor cell lines. Biochem Pharmacol 1994;47:145-149
9. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: A new strategy in cancer treatment. Invest New Drugs 2000;18:109-121 (Pubitemid 30261285)
10. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-2622 (Pubitemid 29269108)
11. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991;19:2499.
12. Lind DS, Hochwald SN, Malaty J, et al. Nuclear factor-κB is upregulated in colorectal cancer. Surgery 2001;130:363-369 (Pubitemid 32721692)
13. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996;274:782-784 (Pubitemid 26398258)
14. Van Antwerp DJ, Martin SJ, Kafri T, et al. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996;274:787-789
15. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241-246 (Pubitemid 32157954)
16. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002;7:9-16.
17. Dejardin E, Deregowski V, Chapelier M, et al. Regulation of NF-κB activity by IκB-related proteins in adenocarcinoma cells. Oncogene 1999;18:2567-2577 (Pubitemid 29216679)
18. Cusack JC, Liu R, Baldwin AS. NF-κB and chemoresistance: potentiation of cancer drugs via inhibition of NF-κB. Drug Resist Update 1999;2:271-273 (Pubitemid 29526249)
19. Cusack JC, Liu R, Baldwin AS. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation. Cancer Res 2000;60:2323-2330
20. Cusack JC, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-KB inhibition. Cancer Res 2001;61:3535-3540 (Pubitemid 32694955)
21. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001;100:11-17 (Pubitemid 32802698)
22. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-3076 (Pubitemid 32691956)
23. Sclabas GM, Dong QG, Fujioka S, et al. Drug-elicited apoptosis in pancreatic tumor cells: The role of different complexes between IκB and NF-κB. Proc Am Assoc Cancer Res 2002;43:882.
24. Ng B, Fong D, Devitt ML, et al. Effect of ionizing radiation with paclitaxel, docetaxel and PS-341 in melanoma cells. Proc Am Assoc Cancer Res 2002;43:480.